Epizyme.com is a ghost in the machine—a biotech company with $834M in funding and $34M in revenue, yet zero detectable web traffic. This isn't a failure; it's a deliberate strategy that reveals the true nature of enterprise healthcare sales.

"In biotech, a zero-traffic website isn't a bug—it's a feature. Epizyme sells to doctors, not consumers."

• Precision oncology focus: Targeting specific genetic alterations in cancer
• Field medical affairs: 329 employees likely include a significant commercial team
• Regulatory complexity: Senior Director of Regulatory Affairs CMC indicates manufacturing scale-up
• Rare disease angle: Hematology/Oncology/Rare Disease focus suggests orphan drug strategy

The tech stack data (or lack thereof) is telling. Zero technologies detected suggests either a highly secure, locked-down infrastructure or a website that's purely informational with minimal tracking. For a biotech with this much funding, it's likely the latter—they're not optimizing for conversion pixels but for HIPAA compliance and regulatory scrutiny. The absence of Trustpilot reviews is expected; you don't rate prescription cancer drugs on consumer review platforms.